Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESUS Fails But Hurt Minimal for Bayer/Janssen's Xarelto

Executive Summary

Bayer and Janssen's bid for NOAC dominance through diversification has hit a buffer with the failure of a Phase III trial in stroke, but the indication is small and not expected to hit sales that much.

Advertisement

Related Content

COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099622

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel